A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In the current study, the authors present pooled data from studies that investigated p53 protein expression and/or mutation in human epithelial ovarian tumors. METHODS: The English literature in the MEDLINE, PubMed, and Ingenta databases was searched to the end of the year 2000 to identify relevant studies. Data were pooled across eligible studies, and the prevalence of p53 expression and mutation among benign, low malignant potential (LMP), and invasive tumors was determined. Prevalence estimates by tumor histology, International Federation of Gynecology and Obstetrics (FIGO) stage, and grade also were calculated. RESULTS: The pooled prevalence estimate for p53 overexpression among epithelial ovarian carcinomas was 51% (95% confidence intervals [95% CI], 50–53%) compared with 17% (95% CI, 15–20%) among LMP tumors and 7% (95% CI, 5–10%) among benign tumors. p53 mutation prevalence estimates were 45% (95% CI, 42–47%), 5% (95% CI, 2–9%), and 1% (95% CI, 0–5%), respectively, for invasive, LMP, and benign tumors. The prevalence of these p53 abnormalities was found to be associated positively with increasing tumor grade and stage. Differences based on histologic subtype also were found. CONCLUSIONS: Although these pooled estimates might appear to offer support for various hypotheses regarding the role of p53 in ovarian carcinoma, the limitations inherent in these data hamper the interpretation of the significance of any of the findings. Future studies will require innovative methods to address the limitations of many previous investigations and more comprehensive investigation into defective tumor suppression mechanisms. Cancer 2003;97:389–404. © 2003 American Cancer Society. DOI 10.1002/cncr.11064
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kosary, C. L. (1994) · Seminars in Surgical Oncology · doi:10.1002/ssu.2980100107 · Cited by 417 · cited 1×
“Alternatively, it might simply reflect the fact that a disproportionate number of serous carcinomas ( 75%) are diagnosed at an advanced stage, compared with clear cell and endometrioid carcinomas (approximately 40–45%).(13,139) Likewise, the rarity of p53 abnormalities among benign ovarian tumors compared with the inc…”
Result
Cited by
Yemelyanova, A., Vang, R., Kshirsagar, M., Lu, D., Marks, M. A., Shih, I. M., & Kurman, R. J. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.85 · Cited by 513
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408
“Given the limitations, p53 immunostaining can therefore not be used as a surrogate for nucleotide sequencing to accurately detect the presence of mutant p53 in ovarian serous tumors, a conclusion consistent with several previous reports.5,11,17 In summary, this study confirms that the usual type of serous carcinoma, w…”
BackgroundResultInfluentialOrigins and molecular pathology of ovarian cancer
Bell, D. A. (2005) · Modern Pathology · doi:10.1016/s0893-3952(22)04456-8 · Cited by 387
Krutzik, P. O., Irish, J. M., Nolan, G. P., & Perez, O. D. (2004) · Clinical Immunology · doi:10.1016/j.clim.2003.11.009 · Cited by 335
Hdmx modulates the outcome of p53 activation in human tumor cells
Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605405200 · Cited by 163
Metadata
- Authors
- Kmet, L. M., Cook, L. S., & Magliocco, A. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-01-03
- Volume
- 97
- Issue
- 2
- Pages
- 389-404
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2014627554
- Cited by
- 108
- References
- 1
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. https://app.cochat.ai/papers/10.1002/cncr.11064
- The paper
- Kmet, L. M., Cook, L. S., & Magliocco, A. M. (2003). A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer. https://doi.org/10.1002/cncr.11064
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.